NCT07187752View on ClinicalTrials.gov

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NANot yet recruitingINTERVENTIONAL
Enrollment

1,039

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)

DRUG

Pertuzumab

Pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks)

DRUG

Chemotherapy

Chemotherapy chosen by the investigators.

PROCEDURE

Excision of tumor/mastectomy

Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER